Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
FIRST has been recognized by MedTech Outlook Magazine as the exclusive recipient of “Top 10 Regenerative Medicine and Surgery Solutions Companies in Europe - 2023,” based on our proprietary methodology, reflecting its position in the industry. This profile has been developed by the MedTech Outlook research and editorial team based on insights from an interview with Ralf Peter Schnorr, eMBA, MD, Founder & CEO.
Ralf Peter Schnorr, eMBA, MD, Founder & CEO
Ensuring a Personalized Approach![]()
We Have Conservative Non-Invasive And Minimally Invasive Treatments, Along With Cell-Based Surgery Treatments That Provide Patients With Effective And Safe Alternatives To Surgeries And Expensive Medication


Company
FIRST
Management
Ralf Peter Schnorr, eMBA, MD, Founder & CEO
Description
FIRST’s regenerative medicine and surgery are centered on stimulating natural healing processes in the body using signaling. Its treatments are categorized as conservative non- and minimally invasive, as well as cell-based surgery. These treatment options trigger rapid tissue regeneration, ensuring a positive step toward normal functions. Apart from regenerative treatment options, FIRST helps with supporting treatments such as physiotherapy and specifically selected supporting drug therapies
Sito Web:
mythras.it
Amministratore:
Roberto Livio Mastronardi, co-fondatore
Descrizione:
Mythras è un team di tecnici specializzati nell'assistenza tecnica su strumentazione IVD, esperti nell'aiutare i responsabili di laboratorio a garantire la precisione, l'accuratezza e la conformità dei loro strumenti. È la scelta ideale per numerosi clienti e distributori, al servizio delle loro complesse esigenze di assistenza tecnica e ricondizionamento della strumentazione IVD.
Citazione:
“Siamo certificati ISO 9001:2015 per l'assistenza tecnica e il ricondizionamento della strumentazione analitica IVD.”
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
